SOL Group ha diffuso questo post
Diatheva has always been a trusted partner of #universities and #research #institutes, providing expertise and all the necessary equipment and technologies. For example, Diatheva was part of the development of a Tat-based vaccine program funded by special funding from the Istituto Superiore della Sanità for Tat vaccine trials, the Italian Concerted Action on HIV-AIDS Vaccine Development (ICAV; National AIDS Programme), the AIDS Vaccine Integrated Project (AVIP; European Commission, grant LSHP-CT-2004-503487), and the Italian Ministries of Health and Foreign Affairs. Its contribution spanned all stages, from development to human trials up to phase IIb. Scroll through the slides to read our case study, or click on the link in the first comment to read the article published by the World Intellectual Property Organization – WIPO.